Inmune Bio ( (INMB) ) has released its Q1 earnings. Here is a breakdown of the information Inmune Bio presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting inflammation and immunology through the innate immune system, with a particular emphasis on diseases like Alzheimer’s and various cancers.
In its first-quarter 2025 earnings report, INmune Bio announced a net loss of $9.7 million, a slight improvement from the $11.0 million loss in the same quarter of the previous year. The company also highlighted several strategic developments across its product platforms, including upcoming trial results and regulatory submissions.
Key financial metrics showed a reduction in research and development expenses to $7.6 million from $8.7 million year-over-year, while general and administrative expenses remained stable at $2.3 million. The company ended the quarter with $19.3 million in cash and cash equivalents, bolstered by a subsequent $2.1 million raised through stock sales. Strategic updates included the anticipated release of Alzheimer’s trial data and plans to file a Biologics License Application for CORDStrom™ in early 2026.
The company is advancing its DN-TNF, CORDStrom™, and INKmune™ platforms, with notable progress in clinical trials and manufacturing partnerships. These developments position INmune Bio to potentially address unmet medical needs in neurodegenerative and inflammatory diseases.
Looking ahead, INmune Bio remains focused on advancing its clinical trials and regulatory submissions, with management expressing optimism about the potential impact of its innovative therapies on patient outcomes.